Suppr超能文献

门诊患者的肠外抗菌治疗在治疗感染性心内膜炎方面是安全有效的:一项回顾性队列研究。

Outpatient parenteral antimicrobial therapy is safe and effective for the treatment of infective endocarditis: a retrospective cohort study.

机构信息

Barwon Health, Geelong, Australia.

出版信息

Intern Med J. 2013 Jun;43(6):700-5. doi: 10.1111/imj.12081.

Abstract

BACKGROUND

Outpatient parenteral antibiotic therapy has been shown to be efficacious, safe and cost-effective for a variety of infections. The data from managing infective endocarditis (IE) with hospital in the home (HITH) are limited. We evaluated the safety and outcomes of patients with IE treated with HITH at our centre.

AIMS

To evaluate the safety, efficacy and 1-year outcomes of patients with IE treated under HITH at our centre over 9 years.

METHOD

A retrospective analysis of the clinical outcomes of all cases of IE treated with HITH at a tertiary referral centre was undertaken for patients treated between June 2002 and July 2011 (9 years). Outcome measures included clinical cure, readmission rate, relapses and 1-year mortality.

RESULTS

Sixty-eight cases of IE were treated with HITH over the study period, including 29 native valve infections, 24 prosthetic valve infections, 12 pacemaker lead infections, 1 defibrillator lead infection, 1 myocardial wall infection and 1 aortic graft infection. Thirteen cases had valve replacement surgery and 12 cases had removal of infected pacemaker leads. Staphylococcus aureus (18 cases), Coagulase-negative staphylococcus (10 cases) and viridians-group streptococcus (18 cases) were the most common pathogens. Median duration of antimicrobial therapy with HITH was 24 days (range 4 to 42 days). There were three readmissions during antimicrobial therapy with HITH. Two patients relapsed. There were two deaths and one patient was lost to follow up. One-year survival was 96% (65/68).

CONCLUSION

Outpatient antimicrobial therapy with HITH is safe and effective in carefully selected cases of IE.

摘要

背景

门诊患者接受抗生素治疗已被证明对多种感染具有疗效、安全性和成本效益。家庭医院(HITH)管理感染性心内膜炎(IE)的数据有限。我们评估了在我们中心使用 HITH 治疗 IE 患者的安全性和结果。

目的

评估 9 年来我们中心使用 HITH 治疗 IE 患者的安全性、疗效和 1 年结果。

方法

对 2002 年 6 月至 2011 年 7 月期间在一家三级转诊中心接受 HITH 治疗的所有 IE 患者的临床结局进行回顾性分析(9 年)。观察指标包括临床治愈、再入院率、复发和 1 年死亡率。

结果

研究期间,有 68 例 IE 患者接受了 HITH 治疗,包括 29 例原发性瓣膜感染、24 例人工瓣膜感染、12 例起搏器导线感染、1 例除颤器导线感染、1 例心肌壁感染和 1 例主动脉移植物感染。13 例患者进行了瓣膜置换手术,12 例患者进行了感染起搏器导线的移除。金黄色葡萄球菌(18 例)、凝固酶阴性葡萄球菌(10 例)和草绿色链球菌(18 例)是最常见的病原体。使用 HITH 进行抗菌治疗的中位时间为 24 天(4 至 42 天)。在使用 HITH 进行抗菌治疗期间有 3 例再入院。2 例患者复发。有 2 例死亡,1 例患者失访。1 年生存率为 96%(65/68)。

结论

在精心选择的 IE 病例中,使用 HITH 进行门诊抗菌治疗是安全有效的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验